BCL2L1 and non-Hodgkin lymphoma: We have previously identified BCL-XL upregulation as a main effector in preventing RAS mutant CRC cell lines from anti-EGFR antibody induced apoptosis, and in CD20-positive B-cell Non-Hodgkin Lymphoma (B-NHL) cells from rituximab-induced apoptosis [33, 57].